Advertisement

Glaucoma pp 47-64 | Cite as

What’s New in Medical Management of Glaucoma

  • Parul Ichhpujani
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

Glaucoma mangement entails use of effective treatment modalities to not only lower but also to maintain intraocular pressure. This chapter reviews the current literature regarding existing pharmacotherapies for glaucoma and those in pipeline.

Keywords

Sustained-release intraocular drug delivery Ocular inserts Drug eluting contact lenses and punctal plugs ROCK inhibitors Short interfering RNAs Adenosine receptor agonists 

References

  1. 1.
    Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123(2):186–92.CrossRefGoogle Scholar
  2. 2.
    Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008;18(3):408–16.CrossRefGoogle Scholar
  3. 3.
    Selen F, Tekeli O, Yanik O. Assessment of the anterior chamber flare and macular thickness in patients treated with topical antiglaucomatous drugs. J Ocul Pharmacol Ther. 2017;33(3):170–5.CrossRefGoogle Scholar
  4. 4.
    Russo A, Riva I, Pizzolante T, et al. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol. 2008;2(4):897–905.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126(4):602–4.CrossRefGoogle Scholar
  6. 6.
    Miyake K, Ibaraki N, Goto Y, et al. ESCRS Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg. 2003;29(9):1800–10.CrossRefGoogle Scholar
  7. 7.
    Abe RY, Zacchia RS, Santana PR, Costa VP. Effects of benzalkonium chloride on the blood-aqueous and blood retinal barriers of pseudophakic eyes. J Ocul Pharmacol Ther. 2014;30(5):413–8.CrossRefGoogle Scholar
  8. 8.
    Razeghinejad MR. The effect of latanaprost on intraocular inflammation and macular edema. Ocul Immunol Inflamm. 2019;27:181–8.CrossRefGoogle Scholar
  9. 9.
    Ohtani S, Shimizu K, Nejima R, Kagaya F, Aihara M, Iwasaki T, Shoji N, Miyata K. Conjunctival bacteria flora of glaucoma patients during long-term administration of Prostaglandin analog drops. Invest Ophthalmol Vis Sci. 2017;58(10):3991–6.CrossRefGoogle Scholar
  10. 10.
    Saji M, Usuki R, Ibaraki N, Hayam N, Osono E, Ohkuni H. Studies of antibacterial activity of benzalkonium chloride as preservative for ophthalmic solutions against gram-positive cocci and negative rods. Jpn J Pharm Health Care Sci. 2003;29:341–5.CrossRefGoogle Scholar
  11. 11.
    Kurihara T, Sugita M, Motai S, Kurashige S. In vitro induction of chlorhexidine- and benzalkonium-resistance in clinically isolated Pseudomonas aeruginosa [in Japanese]. Kansenshogaku Zasshi. 1993;67:202–6.CrossRefGoogle Scholar
  12. 12.
    Cunniffe MG, Medel-Jiménez R, González-Candial M. Topical antiglaucoma treatment with prostaglandin analogues may precipitate meibomian gland disease. Ophthal Plast Reconstr Surg. 2011;27:e128–9.CrossRefGoogle Scholar
  13. 13.
    Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The association of chronic topical prostaglandin analog use with meibomian gland dysfunction. J Glaucoma. 2016;25(9):770–4.CrossRefGoogle Scholar
  14. 14.
    Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93–105.CrossRefGoogle Scholar
  15. 15.
    Choi HY, Lee JE, Lee JW, Park HJ, Lee JE, Jung JH. Invitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadipocytes. J Ocul Pharmacol Ther. 2012;28:146Y52.CrossRefGoogle Scholar
  16. 16.
    Patradul C, Tantisevi V, Manassakorn A. Factors related to prostaglandin-associated periorbitopathy in glaucoma patients. Asia Pac J Ophthalmol (Phila). 2017;6(3):238–42.Google Scholar
  17. 17.
    Skorin L Jr, Dailey KH. Clicking eyelids: a new finding of prostaglandin-associated periorbitopathy. Optom Vis Sci. 2016;93(7):779–81.CrossRefGoogle Scholar
  18. 18.
    Fong CS, Rajak SN, Pirbhai A, Selva D. Audible blink in prostaglandin-associated periorbitopathy. Clin Experiment Ophthalmol. 2016;44(7):630–1.CrossRefGoogle Scholar
  19. 19.
    Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26(4):515–22.CrossRefGoogle Scholar
  20. 20.
    Choi YM, Diehl J, Levins PC. Promising alternative clinical use of prostaglandin F2α analogs: beyond the eyelashes. J Am Acad Dermatol. 2015;72(4):712–6.CrossRefGoogle Scholar
  21. 21.
    Mäenpää J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016;15(11):1549–61.CrossRefGoogle Scholar
  22. 22.
    Inoue T, Tanihara H. Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. Expert Opin Pharmacother. 2017;18(15):1669–73.CrossRefGoogle Scholar
  23. 23.
    Sato S, Hirooka K, Nitta E, et al. Additive intraocular pressure lowering effects of the Rho kinase inhibitor, ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33:1628–34.CrossRefGoogle Scholar
  24. 24.
    Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, dose response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122:302–7.CrossRefGoogle Scholar
  25. 25.
    Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. ROCKET-1 and ROCKET-2 Study Groups. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure. Am J Ophthalmol. 2018;186:116. pii: S0002-9394(17)30513-5.CrossRefGoogle Scholar
  26. 26.
    Schehlein EM, Novack GD, Robin AL. New classes of of glaucoma medications. Curr Opin Ophthalmol. 2017;28(2):161–8.PubMedGoogle Scholar
  27. 27.
    Weinreb RN, Ong T, Scassellati Sforzolini B, et al. for the VOYAGER Study Group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–45.CrossRefGoogle Scholar
  28. 28.
    Weinreb RN, Scassellati SB, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123:965–73.CrossRefGoogle Scholar
  29. 29.
    Vittitow JL, Liebmann JM, Kaufman PL, et al. Long-term efficacy and safety of latanoprostene bunod 0.024% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: APOLLO and LUNAR studies. Invest Ophthalmol Vis Sci. 2016;57(12):3030.Google Scholar
  30. 30.
    Kawase K, Vittitow JL, Weinreb RN, et al. for the JUPITER Study Group. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33:1612–27.CrossRefGoogle Scholar
  31. 31.
    Liu JHK, Slight JR, Vittitow JL, et al. Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours. Am J Ophthalmol. 2016;169:249–57.CrossRefGoogle Scholar
  32. 32.
    Martinez T, Jimenez AI, Paneda C. Short-interference RNAs: becoming medicines. EXCLI J. 2015;14:714–46.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Gonzalez V, Moreno-Montanes J, Oll M, et al. Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma. Poster session presented at Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO), Seattle, WA; 2016.Google Scholar
  34. 34.
    Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucl Acid Ther. 2014;24:258–66.CrossRefGoogle Scholar
  35. 35.
    Filippopoulos T, Ducharme JF, Loewenstein JI, Krzystolik MG. Antiangiogenic agents as an adjunctive treatment for complicated neovascular glaucoma. Invest Ophthalmol Vis Sci. 2006;47:4476.CrossRefGoogle Scholar
  36. 36.
    Bleau A-M, Vargas B, Jiménez AI, Pañeda C. Managing intraocular pressure: innovation in glaucoma management. In: Ichhpujani P, editor. Glaucoma - intraocular pressure and aqueous dynamics. Croatia: InTech; 2016.  https://doi.org/10.5772/65972.CrossRefGoogle Scholar
  37. 37.
    Kalouche G, Beguier F, Bakria M, et al. Activation of prostaglandin FP and EP2 receptors differently modulates myofibroblast transition in a model of adult primary human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2016;57:1816–25.CrossRefGoogle Scholar
  38. 38.
    Ihekoromadu N, Lu F, Iwamura R, et al. Safety and efficacy of DE-117, a selective EP2 agonist in a Phase 2a study. Invest Ophthalmol Vis Sci. 2015;56:5708.Google Scholar
  39. 39.
    Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci. 2015;56:2547–52.CrossRefGoogle Scholar
  40. 40.
    Harris A, Ward CL, Rowe-Rendleman CL, et al. Ocular hypotensive effect of ONO-9054, an EP3/FP receptor agonist: results of a randomized, placebo controlled, dose escalation study. J Glaucoma. 2016;25:e826–33.CrossRefGoogle Scholar
  41. 41.
    Berlin MS, Rowe-Rendleman C, Ahmed I, et al. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol. 2016;100:843–7.CrossRefGoogle Scholar
  42. 42.
    Miller-Ellis EG, Berlin MS, Ward CL, Sharpe J, Jamil A, Harris A, et al. Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan1: results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT). Br J Opthalmol. 2017;101:796–800.CrossRefGoogle Scholar
  43. 43.
    Myers JS, Sall KN, DuBiner H, et al. A Dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2016;32(8):555–62.CrossRefGoogle Scholar
  44. 44.
    Schmeer C, Kretz A, Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci. 2006;24(2):79–95.PubMedGoogle Scholar
  45. 45.
    Pokrovskaya O, Wallace D, O’Brien C. The emerging role of statins in glaucoma pathological mechanisms and therapeutics. Open J Ophthalmol. 2014;4:124–38.CrossRefGoogle Scholar
  46. 46.
    McCann P, Hogg RE, Fallis R, Azuara-Blanco A. The effect of statins on intraocular pressure and on the incidence and progression of glaucoma: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2016;57(6):2729–48.CrossRefGoogle Scholar
  47. 47.
    Talwar N, Musch DC, Stein JD. Association of daily dosage and type of Statin agent with risk of Open-Angle Glaucoma. JAMA Ophthalmol. 2017;135(3):263–7.CrossRefGoogle Scholar
  48. 48.
    Brandt JD, Sall K, DuBiner H, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology. 2016;123:1685–94.CrossRefGoogle Scholar
  49. 49.
    Brandt JD, DuBiner HB, Benza R, Sall KN, Walker GA, Semba CP, Collaborators. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmology. 2017;124(10):1565–6.CrossRefGoogle Scholar
  50. 50.
    Lewis RA, Christie WC, Day DG, et al. Study Group. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase. I/II Clin Trial Am J Ophthalmol. 2017;175:137–47.Google Scholar
  51. 51.
    Ciolino JB, Ross AE, Tulsan R, et al. Latanoprost-eluting contact lenses in glaucomatous monkeys. Ophthalmology. 2016;123:2085–92.CrossRefGoogle Scholar
  52. 52.
    Envisia Therapeutics. Releases ENV515 (travoprost XR) Phase 2 data showing nine-month duration of action after a single dose in patients with glaucoma. Triangle Park, NC: Envisia Therapeutics; 2016. https://www.prnewswire.com/news-releases/envisia-therapeutics-releases-env515-travoprost-xr-phase-2-data-showing-nine-month-duration-of-action-after-a-single-dose-in-patients-with-glaucoma-300345633.html.Google Scholar
  53. 53.
    Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol (Auckland, NZ). 2016;10:757–64.CrossRefGoogle Scholar
  54. 54.
    Mati Therapeutics. Mati Therapeutics selected to present at Ocular Innovation Summit: pursuing sustained ocular drug delivery programs in inflammation, pain, and glaucoma, 3 October. Austin, TX: Mati Therapeutics; 2016. Accessed Jan 2018. Available at www.matitherapeutics.com/about/press/ocular-innovation-summit.Google Scholar
  55. 55.
    www.psivida.com/products.html. Accessed 13 Jan 2018.
  56. 56.
    www.replenishinc.com. Accessed 13 Jan 2018.
  57. 57.
  58. 58.
    Lavik E, Kuehn MH, Shoffstall AJ, Atkins K, Dumitrescu AV, Kwon YH. Sustained delivery of timolol maleate for over 90 days by subconjunctival injection. J Ocul Pharmacol Ther. 2016;32(10):642–9.CrossRefGoogle Scholar
  59. 59.
    Di Zazzo A, Roberti G, Mashaghi A, Abud TB, Pavese D, Bonini S. Use of topical cannabinomimetic palmitoylethanolamide in ocular surface disease associated with antiglaucoma medications. J Ocul Pharmacol Ther. 2017;33(9):670–7.CrossRefGoogle Scholar
  60. 60.
    Gipson IK. Goblet cells of the conjunctiva: a review of recent findings. Prog Retin Eye Res. 2016;54:49–63.CrossRefGoogle Scholar
  61. 61.
    Kawaguchi I, Kobayashi A, Higashide T, Takeji Y, Sakurai K, Kawaguchi C, Sugiyama K. Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits. PLoS One. 2017;12(10):e0186714.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Parul Ichhpujani
    • 1
  1. 1.Glaucoma Service, Department of OphthalmologyGovernment Medical College and HospitalChandigarhIndia

Personalised recommendations